Puma Biotechnology Inc PBYI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
2.37UNCH (UNCH)
Volume
202
Close
2.37quote price arrow up+0.10 (+4.41%)
Volume
93,646
52 week range
1.60 - 7.73
Loading...
  • Open2.31
  • Day High2.40
  • Day Low2.31
  • Prev Close2.27
  • 52 Week High7.73
  • 52 Week High Date09/28/21
  • 52 Week Low1.60
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap107.98M
  • Shares Out45.56M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta0.68
  • YTD % Change-22.04

KEY STATS

  • Open2.31
  • Day High2.40
  • Day Low2.31
  • Prev Close2.27
  • 52 Week High7.73
  • 52 Week High Date09/28/21
  • 52 Week Low1.60
  • 52 Week Low Date05/12/22
  • Market Cap107.98M
  • Shares Out45.56M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta0.68
  • YTD % Change-22.04

RATIOS/PROFITABILITY

  • EPS (TTM)-0.87
  • P/E (TTM)-2.74
  • Fwd P/E (NTM)-
  • EBITDA (TTM)18.387M
  • ROE (TTM)-140.14%
  • Revenue (TTM)206.86M
  • Gross Margin (TTM)76.83%
  • Net Margin (TTM)-16.67%
  • Debt To Equity (MRQ)494.89%

EVENTS

  • Earnings Date11/02/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Puma Biotechnology Inc

 

Profile

MORE
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. It is primarily focused on the development and commercialization of the oral version...
Alan Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Maximo Nougues
Chief Financial Officer
Address
SUITE 2150, 10880 WILSHIRE BLVD.
Los Angeles, CA
90024
United States

Top Peers

SYMBOLLASTCHG%CHG
CLVS
Clovis Oncology Inc
1.18+0.13+12.38%
HBIO
Harvard Bioscience Inc
2.56+0.23+9.87%
AKBA
Akebia Therapeutics Inc
0.33+0.0258+8.48%
ATNX
Athenex Inc
0.2826+0.0176+6.64%
MDXG
MiMedx Group Inc
3.06+0.22+7.75%